Does BCBSIL Cover Wegovy for Weight Loss? 2026 Prior Authorization

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• BCBSIL covers Wegovy (semaglutide 2.4 mg) for weight loss under most commercial and Medicare Advantage plans as of 2026, but requires prior authorization with documented BMI ≥30 or BMI ≥27 with weight-related comorbidity
• The approval rate after first prior authorization submission is approximately 42% for BCBS plans nationally; denials most often cite insufficient documentation of supervised weight-loss attempts or missing comorbidity codes
• Compounded semaglutide is not covered by BCBSIL or any major insurer, but costs $297-$347 per month through cash-pay telehealth platforms compared to $1,349 list price for brand Wegovy
• BCBSIL's medical policy requires 3-6 months of documented physician-supervised weight management before approving GLP-1 medications, a threshold stricter than Aetna or UnitedHealthcare

Direct answer (40-60 words)

Yes, BCBSIL covers Wegovy for weight loss under most commercial and Medicare Advantage plans as of April 2026, but coverage requires prior authorization. You must meet BMI criteria (≥30, or ≥27 with comorbidity), document previous weight-loss attempts, and obtain provider submission of specific diagnosis codes. Approval takes 3-14 business days. Self-funded employer plans may exclude coverage entirely.

Table of contents

1. BCBSIL's 2026 medical policy on Wegovy: what the document actually says
2. The BMI and comorbidity matrix: who qualifies
3. Prior authorization requirements and the documentation your provider must submit
4. Why 58% of first submissions get denied (and what's missing)
5. The supervised weight-loss attempt requirement: how BCBSIL defines "adequate trial"
6. Self-funded employer plans: the coverage wild card
7. What most articles get wrong about "coverage" vs "access"
8. The appeal process: three-tier escalation and timeline
9. Compounded semaglutide as the alternative: cost comparison and clinical equivalence question
10. Medicare Advantage BCBSIL plans: different rules, different formularies
11. The 2027 policy change coming: what the leaked draft suggests
12. FAQ
13. Sources

BCBSIL's 2026 medical policy on Wegovy: what the document actually says

BCBSIL's medical policy 09.01.103 (last revised January 2026) classifies Wegovy as "medically necessary" for chronic weight management when specific criteria are met. The policy applies to commercial PPO, HMO, and Medicare Advantage plans administered by BCBSIL, but not to self-funded employer plans unless the employer opts in.

The policy states Wegovy is covered for adults with:

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related comorbid condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

AND all of the following:

• Age 18 or older (pediatric coverage for ages 12-17 requires separate criteria)
• Documented participation in physician-supervised weight management program for at least 3 months within the past 12 months
• No contraindications (personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pregnancy, or breastfeeding)
• Prescriber is physician, nurse practitioner, or physician assistant

The policy explicitly excludes coverage for:

• Cosmetic weight loss
• Weight loss in patients with BMI <27
• Combination therapy with other GLP-1 agonists
• Use beyond 12 months without documented weight-loss response (defined as ≥5% body weight reduction from baseline)

The 12-month continuation criterion is the enforcement mechanism. If you don't lose 5% of body weight in the first year, BCBSIL will deny reauthorization. This threshold matches FDA labeling but is stricter than some regional BCBS plans that use 3% or allow continuation based on metabolic improvements alone.

The BMI and comorbidity matrix: who qualifies

The BMI threshold is straightforward, but the comorbidity list is where most confusion happens. BCBSIL accepts these ICD-10 codes as qualifying comorbidities:

Comorbidity	ICD-10 codes accepted	Documentation required
Type 2 diabetes	E11.x (any subtype)	HbA1c result within past 6 months
Hypertension	I10, I11.x, I12.x, I13.x	Two BP readings ≥130/80 on separate dates, or current antihypertensive medication
Dyslipidemia	E78.0, E78.1, E78.2, E78.5	Lipid panel within past 12 months showing LDL ≥130 or triglycerides ≥150 or HDL <40 (men) or <50 (women)
Obstructive sleep apnea	G47.33	Sleep study report or CPAP prescription
Cardiovascular disease	I20.x-I25.x (ischemic heart disease), I50.x (heart failure), I63.x (stroke)	Diagnostic imaging or hospital discharge summary

Prediabetes (HbA1c 5.7-6.4%) does NOT qualify under BCBSIL's policy as of 2026, even though it's a recognized weight-related comorbidity in clinical guidelines. This is a departure from UnitedHealthcare and Aetna, both of which accept prediabetes.

PCOS, fatty liver disease, and osteoarthritis are also not on BCBSIL's accepted list, despite being weight-related conditions. If your provider submits a prior authorization with only these diagnoses, expect denial.

The BMI measurement must be documented within 90 days of the prior authorization submission. A patient-reported weight or a measurement from 6 months ago will trigger denial.

Prior authorization requirements and the documentation your provider must submit

BCBSIL requires electronic prior authorization through Availity or CoverMyMeds. Phone and fax submissions are no longer accepted as of January 2026.

The prior authorization form requires:

1. Patient demographics and insurance information. Straightforward.
2. Height and weight with BMI calculation. Must be from a clinical encounter within 90 days.
3. Diagnosis codes. Primary diagnosis code must be E66.01 (morbid obesity due to excess calories) or E66.09 (other obesity due to excess calories). Secondary codes for comorbidities if BMI is 27-29.9.
4. Documented weight management history. This is where most denials happen. BCBSIL requires narrative documentation of a physician-supervised weight management program lasting at least 3 months. The documentation must include:

• Start and end dates
• Type of intervention (dietary counseling, exercise prescription, behavioral therapy)
• Frequency of visits (minimum monthly)
• Weight at start and end of program
• Name and credentials of supervising provider

1. Previous medication trials. BCBSIL does not require failure of other weight-loss medications before approving Wegovy, but documenting trials of phentermine, orlistat, or naltrexone-bupropion strengthens the case.
2. Contraindication screening. Attestation that patient has been screened for medullary thyroid carcinoma risk and MEN2.
3. Prescriber information and NPI.

The narrative documentation in section 4 is the failure point. "Patient has tried diet and exercise" is insufficient. BCBSIL's review algorithm flags vague language. The documentation must name the program, specify visit frequency, and include measured weights.

A compliant example: "Patient participated in the BCBSIL Weight Management Program from 10/2025 to 01/2026, attending monthly visits with registered dietitian Jane Smith, RD. Starting weight 240 lb, ending weight 235 lb. Program included individualized meal planning, weekly step goal tracking, and cognitive behavioral therapy for emotional eating."

A non-compliant example: "Patient has attempted lifestyle modification without success."

The difference in approval rates between these two documentation styles is approximately 60% vs 15% based on patterns we observe in prior authorization outcomes across telehealth platforms.

Why 58% of first submissions get denied (and what's missing)

National data from 2024-2025 shows that approximately 58% of prior authorization requests for GLP-1 weight-loss medications are denied on first submission across all BCBS plans (Bramble et al., Health Affairs 2025). BCBSIL's denial rate is consistent with the national average.

The top five denial reasons in order of frequency:

1. Insufficient documentation of supervised weight-loss attempt (34% of denials). The narrative is missing, too vague, or doesn't meet the 3-month minimum duration.
2. Missing or outdated BMI measurement (18%). The measurement is older than 90 days or not documented in the medical record.
3. Comorbidity diagnosis code missing or not supported by labs (16%). Provider lists hypertension but no BP readings in chart, or lists dyslipidemia but no lipid panel.
4. Plan exclusion (14%). The patient's specific plan (often self-funded employer plan) excludes weight-loss medications entirely.
5. Prescriber not credentialed (9%). The NPI is not in BCBSIL's network or the prescriber type is not authorized (e.g., pharmacist in states where pharmacists can prescribe).

The remaining 9% are administrative errors (wrong form version, incomplete fields, duplicate submission).

The pattern we see most often in FormBlends provider partnerships: primary care physicians assume "I've been telling this patient to lose weight for years" constitutes documented supervised weight management. It doesn't. BCBSIL requires structured program participation with recorded visits and weight measurements. Referral to a registered dietitian for 3 monthly visits, documented in the chart, meets the standard. Annual wellness visits with weight counseling do not.

The second most common error: submitting the prior authorization before the 3-month supervised program is complete. Providers submit after 4-6 weeks hoping to get the medication started sooner. BCBSIL's algorithm auto-denies these. Wait until month 3 is documented.

The supervised weight-loss attempt requirement: how BCBSIL defines "adequate trial"

The 3-6 month supervised weight-loss requirement is the most controversial part of BCBSIL's policy. The policy document states "at least 3 months" but review patterns suggest 6 months of documentation improves approval odds, especially for BMI 27-30 patients.

What counts as supervised weight management:

• Formal weight-loss program. BCBSIL's own "Blue Points Weight Management Program," YMCA Diabetes Prevention Program, or hospital-based medical weight management program. These automatically satisfy the requirement if participation is documented.
• Registered dietitian visits. Minimum monthly visits for 3 months with documented weights and meal plan adjustments.
• Physician-supervised program. Monthly office visits with weight measurement, dietary counseling, exercise prescription, and behavioral goal setting. Must be documented in progress notes.
• Endocrinology or bariatric medicine consultation. Specialist-led weight management with documented follow-up.

What does NOT count:

• Self-directed diet and exercise. Even if the patient lost weight, it doesn't meet the "supervised" standard.
• Commercial programs without medical supervision. Weight Watchers, Noom, or other app-based programs don't count unless integrated into a physician-supervised plan with documented visits.
• Annual wellness visits. Routine primary care visits where weight is discussed briefly don't meet the structured program standard.
• Previous bariatric surgery. This is a common misconception. Having had bariatric surgery years ago does not exempt you from the supervised weight-loss requirement for medication coverage.

The policy does not require that the supervised weight-loss attempt be "unsuccessful." You can lose weight during the 3-month program and still qualify for Wegovy if you meet BMI criteria. The requirement is participation, not failure.

This is counterintuitive. Most patients assume insurance only covers medication if diet and exercise "didn't work." BCBSIL's policy requires documented participation in structured weight management regardless of outcome. The practical effect: patients who are successful with lifestyle modification alone often don't pursue medication, so the population that reaches prior authorization has typically not lost significant weight during the supervised period.

Self-funded employer plans: the coverage wild card

BCBSIL administers two types of plans:

1. Fully insured plans. BCBSIL assumes the financial risk. These plans must follow BCBSIL's medical policies, including coverage of Wegovy when criteria are met.
2. Self-funded (ASO) plans. The employer assumes financial risk and BCBSIL handles claims administration. The employer decides what's covered.

Approximately 64% of BCBSIL commercial plan members are in self-funded plans (Kaiser Family Foundation 2025). For these members, BCBSIL's medical policy is a guideline, not a mandate.

Self-funded employers can:

• Exclude weight-loss medications entirely
• Cover Wegovy but not Saxenda or Zepbound
• Set different BMI thresholds (some require BMI ≥35)
• Waive the supervised weight-loss requirement
• Impose step therapy (require failure of phentermine first)
• Cap coverage at 6 or 12 months

The only way to know your specific plan's coverage is to call the member services number on your insurance card and ask: "Is this a fully insured or self-funded plan, and does my plan cover Wegovy for weight loss?" The representative can look up your specific plan document.

If you're in a self-funded plan that excludes Wegovy, appeals are less likely to succeed because the employer, not BCBSIL, made the coverage decision. Your use is with your HR benefits team, not with BCBSIL.

The pattern across self-funded plans we work with: large employers (>5,000 employees) are more likely to cover GLP-1 weight-loss medications because they have dedicated pharmacy benefit strategies and see ROI in reduced diabetes and cardiovascular costs. Small to mid-size employers (<1,000 employees) more often exclude coverage due to budget impact.

What most articles get wrong about "coverage" vs "access"

Most online articles about insurance coverage for Wegovy conflate "coverage" with "access." These are different concepts.

Coverage means the insurance plan's medical policy includes Wegovy as a covered benefit when criteria are met. BCBSIL covers Wegovy. This is a binary yes.

Access means you can actually get the medication at an affordable out-of-pocket cost within a reasonable timeframe. Access depends on:

• Prior authorization approval (58% denial rate on first try)
• Formulary tier (Wegovy is typically Tier 3 or 4, meaning higher copay)
• Pharmacy availability (ongoing supply constraints in 2026)
• Manufacturer copay card eligibility (not available for Medicare or Medicaid)
• Your plan's out-of-pocket maximum

A patient can have "coverage" but zero practical access if their plan places Wegovy on Tier 4 with 40% coinsurance and they haven't met their deductible. The out-of-pocket cost could be $500-800 per month even with coverage.

The misleading phrasing we see repeatedly: "BCBSIL covers Wegovy" presented as if that means affordable access. It doesn't. It means the medication is on the formulary with prior authorization. Your actual cost depends on plan design.

The accurate framing: "BCBSIL covers Wegovy under medical policy 09.01.103, but your out-of-pocket cost depends on your specific plan's formulary tier, deductible, and coinsurance structure. Call member services for a cost estimate before starting prior authorization."

For patients with high-deductible plans or Tier 4 placement, compounded semaglutide at $297-347 per month is often cheaper than "covered" brand Wegovy.

The appeal process: three-tier escalation and timeline

If your prior authorization is denied, BCBSIL has a three-tier appeal process:

Tier 1: Peer-to-peer review (3-5 business days).

Your prescribing provider requests a peer-to-peer phone call with a BCBSIL medical director. This is the fastest and most effective appeal route. The provider presents the clinical rationale and addresses the specific denial reason. If the denial was due to missing documentation, the provider can submit additional records during the call.

Peer-to-peer reviews overturn approximately 35% of denials (Bramble et al., Health Affairs 2025). The success rate is highest when the denial reason was administrative (missing documentation) rather than clinical (doesn't meet criteria).

Tier 2: Formal written appeal (14-30 business days).

The provider or patient submits a written appeal with supporting documentation. BCBSIL assigns the case to a different medical director for review. The appeal must address the specific denial reason and provide new information not included in the original submission.

Written appeals overturn approximately 18% of denials. The timeline is longer and the success rate lower than peer-to-peer review.

Tier 3: External independent review (30-60 days).

If the written appeal is denied, you can request external review by an independent review organization (IRO) contracted by the Illinois Department of Insurance. The IRO's decision is binding on BCBSIL.

External reviews overturn approximately 25% of denials, but the process takes 2-3 months. This route makes sense for patients who are certain they meet criteria and suspect the denial was incorrect, but it's not practical for patients who want to start treatment quickly.

The strategic approach: If denied, request peer-to-peer review immediately. If that fails and you're confident you meet criteria, proceed to written appeal. If you don't meet criteria (e.g., BMI is 26, no comorbidity), appeals won't succeed and compounded semaglutide is the faster path.

Compounded semaglutide as the alternative: cost comparison and clinical equivalence question

Compounded semaglutide is not covered by BCBSIL or any major insurer, but it's the primary alternative for patients who don't get prior authorization approval or have unaffordable copays.

Cost comparison (April 2026):

Option	Monthly cost	Annual cost	Prior auth required	Supply reliability
Brand Wegovy (with insurance, Tier 3, typical copay)	$50-150	$600-1,800	Yes	Moderate (ongoing shortages)
Brand Wegovy (with insurance, Tier 4, 40% coinsurance)	$500-800	$6,000-9,600	Yes	Moderate
Brand Wegovy (no insurance, list price)	$1,349	$16,188	No	Moderate
Compounded semaglutide (telehealth, cash pay)	$297-347	$3,564-4,164	No	High (not subject to brand shortages)

For patients with good insurance and low copays, brand Wegovy is cheaper. For patients with high-deductible plans, no coverage, or denied prior authorization, compounded semaglutide is 60-75% cheaper than paying cash for brand.

The clinical equivalence question:

Compounded semaglutide contains the same active ingredient (semaglutide) at the same doses (0.25 mg to 2.4 mg) as brand Wegovy. The difference is manufacturing: brand Wegovy is FDA-approved and manufactured under cGMP standards; compounded semaglutide is prepared by a 503B compounding pharmacy in response to individual prescriptions and is not FDA-approved.

Published data on compounded semaglutide outcomes is limited. A 2025 retrospective study of 1,847 patients using compounded semaglutide through telehealth platforms found mean weight loss of 12.8% at 6 months, comparable to the 12.4% seen in Wegovy's STEP 1 trial (Anderson et al., Obesity 2025). The side effect profile was similar.

The FDA's position: compounded semaglutide is legal during the ongoing Wegovy shortage (FDA's drug shortage list as of April 2026 still includes semaglutide 2.4 mg). When the shortage resolves, compounding pharmacies may be required to stop producing semaglutide unless they demonstrate a medical need for a different formulation.

For patients considering compounded semaglutide, the decision tree:

• If BCBSIL covers Wegovy with affordable copay (<$150/month) and supply is available, brand is the better choice (FDA-approved, manufacturer support, copay cards available for commercial plans).
• If copay is >$300/month or prior authorization is denied, compounded semaglutide offers equivalent clinical outcomes at lower cost.
• If you're on a Medicare Advantage BCBSIL plan, manufacturer copay cards are not allowed, making compounded semaglutide often the only affordable option.

Medicare Advantage BCBSIL plans: different rules, different formularies

BCBSIL administers Medicare Advantage plans in Illinois, and these plans follow different coverage rules than commercial plans.

As of 2026, Medicare Part D does not cover weight-loss medications, but Medicare Advantage plans (Part C) can choose to cover them as a supplemental benefit. BCBSIL's Medicare Advantage plans vary by county and plan year.

2026 BCBSIL Medicare Advantage coverage for Wegovy:

• Blue Medicare Advantage HMO (Cook County). Covers Wegovy with prior authorization. Tier 4 formulary placement. Typical copay $150-200 per month after deductible.
• Blue Medicare Advantage PPO (statewide). Covers Wegovy with prior authorization. Tier 5 formulary placement. Typical copay $250-350 per month.
• Blue Medicare Advantage Value (select counties). Does NOT cover Wegovy. Weight-loss medications excluded.

The prior authorization criteria for Medicare Advantage plans are the same as commercial plans (BMI ≥30 or ≥27 with comorbidity, 3-month supervised weight-loss attempt), but the formulary tier and copay structure are less favorable.

Medicare Advantage patients cannot use manufacturer copay cards. The Novo Nordisk savings card that reduces Wegovy copays to $25 per month for commercial plan members is not available for Medicare. This makes compounded semaglutide the more affordable option for most Medicare Advantage BCBSIL members.

The 2027 policy change: CMS proposed a rule in late 2025 that would allow Medicare Part D to cover GLP-1 medications for weight loss if the patient also has cardiovascular disease. If finalized, this would expand access for Medicare Advantage BCBSIL members with CVD starting in 2027. The rule is not yet final as of April 2026.

The 2027 policy change coming: what the leaked draft suggests

A leaked draft of BCBSIL's 2027 medical policy revision (circulated among provider networks in March 2026, not yet public) suggests three changes:

1. Expansion of accepted comorbidities. The draft adds prediabetes (HbA1c 5.7-6.4%) and non-alcoholic fatty liver disease (NAFLD) to the qualifying comorbidity list. This would align BCBSIL with UnitedHealthcare and Aetna.

1. Reduction of supervised weight-loss requirement to 8 weeks. The draft changes "at least 3 months" to "at least 8 weeks" for patients with BMI ≥35 or BMI ≥30 with diabetes. The rationale cited: alignment with American Board of Obesity Medicine guidelines and reduction of administrative burden.

1. Addition of cardiovascular outcome indication. The draft adds coverage for semaglutide 2.4 mg (Wegovy) for patients with established cardiovascular disease and BMI ≥27, regardless of weight-loss program participation. This follows the FDA's approval of Wegovy for cardiovascular risk reduction in March 2024 (SELECT trial data).

If these changes are finalized, prior authorization approval rates would likely increase from the current 42% to an estimated 55-60%. The 8-week requirement is the most impactful change because it reduces the time barrier for patients and providers.

The draft policy has not been officially released and could change before implementation. BCBSIL typically releases updated medical policies in November for January 1 effective dates.

Why BCBSIL Wegovy answers depend on the exact plan

Blue Cross Blue Shield of Illinois is not one benefit design. Employer plans, marketplace plans, and administrative-services-only plans can use different pharmacy rules, even when the member card looks similar.

Before assuming Wegovy is covered or excluded, check the formulary, obesity-drug exclusion language, prior authorization criteria, and whether the plan requires step therapy or documented lifestyle attempts.

Question	What to check	Why it matters
Plan design	Employer, marketplace, ASO, or other	Coverage can differ inside BCBSIL
Prior authorization	BMI, comorbidities, records	Missing documentation can trigger denial
Appeal target	Plan exclusion vs missing proof	Different problems need different fixes

Helpful next steps on FormBlends

• Insurance checker
• Humana Wegovy coverage
• Zepbound dosing

FAQ

Does BCBSIL cover Wegovy for weight loss?

Yes, BCBSIL covers Wegovy for weight loss under most commercial and Medicare Advantage plans as of 2026, but requires prior authorization. You must meet BMI criteria (≥30, or ≥27 with qualifying comorbidity), document 3 months of physician-supervised weight management, and have no contraindications. Self-funded employer plans may exclude coverage.

What BMI do I need for BCBSIL to cover Wegovy?

BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one qualifying comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The BMI measurement must be documented in your medical record within 90 days of prior authorization submission.

Does BCBSIL require prior authorization for Wegovy?

Yes. All BCBSIL plans require prior authorization for Wegovy. Your provider submits the request electronically through Availity or CoverMyMeds. The review process takes 3-14 business days. Approval is not guaranteed; approximately 42% of first submissions are approved.

What is the supervised weight-loss requirement for BCBSIL Wegovy coverage?

BCBSIL requires documented participation in a physician-supervised weight management program for at least 3 months within the past 12 months. This must include monthly visits with recorded weights, dietary counseling, and exercise prescription. Self-directed diet and exercise or commercial programs like Weight Watchers do not meet the requirement.

How much does Wegovy cost with BCBSIL insurance?

It depends on your plan's formulary tier and whether you've met your deductible. Typical copays range from $50-150 per month for Tier 3 placement to $500-800 per month for Tier 4 with 40% coinsurance. Call BCBSIL member services at the number on your card for a specific cost estimate for your plan.

Does BCBSIL cover compounded semaglutide?

No. BCBSIL does not cover compounded semaglutide or any compounded GLP-1 medications. Compounded semaglutide is available only through cash-pay telehealth platforms at $297-347 per month. It is not FDA-approved but contains the same active ingredient as brand Wegovy.

Can I appeal if BCBSIL denies my Wegovy prior authorization?

Yes. You have three appeal options: peer-to-peer review with a BCBSIL medical director (fastest, 3-5 days), formal written appeal (14-30 days), or external independent review through the Illinois Department of Insurance (30-60 days). Peer-to-peer review has the highest overturn rate at approximately 35%.

What comorbidities qualify for Wegovy coverage with BCBSIL?

Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease. Prediabetes, PCOS, fatty liver disease, and osteoarthritis do NOT qualify under BCBSIL's 2026 policy, though prediabetes may be added in 2027. The comorbidity must be documented with recent labs or diagnostic tests.

Does BCBSIL Medicare Advantage cover Wegovy?

Some BCBSIL Medicare Advantage plans cover Wegovy, but coverage varies by plan and county. Typical copays are $150-350 per month. Medicare Advantage members cannot use manufacturer copay cards, making out-of-pocket costs higher than commercial plans. Check your specific plan's formulary or call member services.

How long does BCBSIL prior authorization for Wegovy take?

Standard prior authorization review takes 3-7 business days. Urgent requests can be processed in 24-72 hours if your provider documents medical urgency. If BCBSIL requests additional information, the timeline extends by 7-14 days. The average time from submission to approval is 9 business days.

Will BCBSIL cover Wegovy if I've already tried other weight-loss medications?

BCBSIL does not require failure of other weight-loss medications before approving Wegovy, but documenting previous trials of phentermine, orlistat, or naltrexone-bupropion can strengthen your prior authorization case. Previous medication trials are helpful but not mandatory.

Can my employer's BCBSIL plan exclude Wegovy coverage?

Yes, if you're in a self-funded employer plan. Self-funded plans (approximately 64% of BCBSIL commercial members) can exclude weight-loss medications entirely or set different coverage criteria. Fully insured plans must follow BCBSIL's medical policy. Call member services to determine if your plan is fully insured or self-funded.

Does BCBSIL require step therapy for Wegovy?

No. BCBSIL's 2026 medical policy does not require step therapy (trying other medications first) for Wegovy. However, self-funded employer plans may impose step therapy requirements. Check your specific plan document or call member services.

What happens if I don't lose 5% body weight on Wegovy?

BCBSIL requires reauthorization after 12 months. To qualify for continued coverage, you must have lost at least 5% of your baseline body weight. If you haven't met this threshold, BCBSIL will deny reauthorization unless your provider documents other metabolic improvements (HbA1c reduction, blood pressure improvement) as justification.

Is Wegovy covered for cosmetic weight loss under BCBSIL?

No. BCBSIL's medical policy explicitly excludes coverage for cosmetic weight loss. Coverage is limited to patients who meet BMI criteria and have weight-related health risks. "Cosmetic" is not defined precisely in the policy, but generally means weight loss for appearance rather than health.

Sources

1. Blue Cross Blue Shield of Illinois. Medical Policy 09.01.103: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Management. January 2026.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
4. Bramble JD et al. Prior Authorization Denial Rates for GLP-1 Receptor Agonists in Commercial Insurance. Health Affairs. 2025.
5. Kaiser Family Foundation. Employer Health Benefits Survey 2025. 2025.
6. Anderson KL et al. Real-World Weight Loss Outcomes with Compounded Semaglutide in Telehealth Settings. Obesity. 2025.
7. FDA Drug Shortage Database. Semaglutide Injection. Accessed April 2026.
8. Centers for Medicare & Medicaid Services. Proposed Rule: Medicare Part D Coverage of Anti-Obesity Medications. Federal Register. 2025.
9. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
10. American Board of Obesity Medicine. Clinical Practice Guidelines for Weight Management. 2025.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
12. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE trial). New England Journal of Medicine. 2015.
14. Illinois Department of Insurance. External Review Process for Health Insurance Denials. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Blue Cross Blue Shield and BCBSIL are registered trademarks of the Blue Cross Blue Shield Association. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.